Stay updated on Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA unified Locations section listing study sites by state (California, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New York, North Carolina, Ohio, Texas) was added, and the previous state-specific location subsections were removed. The revision tag updated from v3.3.2 to v3.3.3.SummaryDifference1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.3.2 replaces v3.3.1 on the page, indicating a minor version update with no changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedPublications section updates add clarifications that publications are provided voluntarily by the study submitter and that PubMed data is auto-filled and may not always pertain to the study; a system revision tag v3.3.1 was added. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check52 days agoChange DetectedRemoved the government funding/operating status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check66 days agoChange DetectedThe new screenshot shows only cosmetic layout and styling updates to the study page; the study content, eligibility criteria, and locations remain the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check95 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference4%

Stay in the know with updates to Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial page.